{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-137210","form_type":"8-K","ticker":"FBRX","cik":"0001419041","company_name":"Forte Biosciences, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.332560+00:00","generated_at":"2026-06-02T02:06:19.546498+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Forte Biosciences Q1 net loss $0.16/shr; cash $30.4M; FB102 SAD completed, MAD ongoing","bullets":["Net loss $7.4M ($0.16/shr) vs $6.8M ($0.32/shr) in Q1 2023; weighted avg shares 46.1M (incl. pre-funded warrants).","R&D expense $4.4M (down $0.4M); G&A $3.5M (up $1.4M on legal/professional costs).","Cash & equivalents $30.4M at Mar 31, 2024, down from $37.1M at Dec 31, 2023.","FB102 Phase 1 SAD completed; MAD cohorts expected to complete mid-2024; patient studies planned before year-end.","Company updated corporate presentation (Exhibit 99.2) for investor meetings."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-137210","json":"https://secwatch.observer/filing/0001193125-24-137210.json","markdown":"https://secwatch.observer/filing/0001193125-24-137210.md","text":"https://secwatch.observer/filing/0001193125-24-137210.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419041/000119312524137210/0001193125-24-137210-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419041/000119312524137210/d825808d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:06:19.546498+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4344c7c9a3892373671a76ea22ad2bd0fdc0be06","claim":"Forte Biosciences, Inc. reported the quarter ended March 31, 2024 results: net income $(7,420 ), EPS $(0.16 ).","evidence_excerpt":"On May 13, 2024, Forte Biosciences, Inc. issued a press release reporting its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1419041/000119312524137210/0001193125-24-137210-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"$(7,420 )"},{"label":"EPS","value":"$(0.16 )"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}